glp·helper
glphelper.com/zepbound/texas/grapevine
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in Grapevine, TX

Verified Zepbound providers in Grapevine, TX. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Zepbound weight loss →trial-anchored estimate
city providers
26
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Texas
27 of 27 shown

Find a Zepbound provider in Texas.

Every entry is checked against the NPI registry and the Texas medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Texas city · /zepbound/texas/{city}
§ 03Getting Zepbound in Grapevine
27 providers · Grapevine, TX

How to get Zepbound in Grapevine.

27 GLP-1 prescribers and 7 local resource types are on record for Grapevine, plus 3 nearby towns in the directory.

Prescribers in Grapevine
27 prescribers
27 GLP-1 prescribers in Grapevine, most listed as Family Medicine (13), Internal Medicine (12) and Internal Medicine, Endocrinology, Diabetes & Metabolism (1). Any Texas-licensed physician, nurse practitioner, or PA can prescribe Zepbound, over video or in person. The nearest towns on record are Southlake (26 providers), Coppell (28 providers) and Euless (30 providers).
Around the prescription in Grapevine
7 listed nearby
6 dietitians, 2 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Grapevine.
Medicaid (weight loss)
Diabetes only
As of April 2026, Texas Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Texas’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition)
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Grapevine

Grapevine, Texas has a population of 50,631 people. The adult obesity rate in Grapevine is an age-adjusted estimate of 28.8%, 6.8 percentage points below the Texas state rate of 35.6%. Diagnosed diabetes reaches 8.6% of adults in Grapevine. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 20.8% of adults in Grapevine.

of Grapevine adults have obesity
28.8%
diagnosed diabetes
8.6%
no regular physical activity
20.8%

Age-adjusted estimates for Grapevine, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losswhat happens after GLP-1s stop
§ 05Support around Zepbound in Grapevine
6 gyms

The prescription is one part. Here is the rest, in Grapevine.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Grapevine, TX, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Fitness Connection
GYM
4.4 on Google · 3079 reviews
3888 Irving Mall
Website
EōS Fitness
GYM
4.3 on Google · 2167 reviews
2401 Rio Grande Blvd
Website
Absolute Recomp Las Colinas
GYM
4.9 on Google · 2052 reviews
2000 Market Pl Blvd Ste 150
Website
Absolute Recomp North Richland Hills
GYM
4.8 on Google · 1885 reviews
6428 Davis Blvd #100
Website
LA Fitness
GYM
3.2 on Google · 1309 reviews
5550 N MacArthur Blvd
Website
Planet Fitness
GYM
4.3 on Google · 1024 reviews
500 E Round Grove Rd #201
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Samira Amlani, RD LD
RD
Registered dietitian
3636 N Macarthur Blvd Ste 120
Call 469-565-2539NPI 1043567241
Vicki Bailey, MS, RD, LD
RD
Registered dietitian
1650 W College St
Call 817-424-4669NPI 1811521610
Melissa Brown, RD LD
RD
Registered dietitian
3800 Grapevine Mills Pkwy Apt 836
Call 318-558-1426NPI 1649515909
Brittney Carroll, MBA, RDN, LDN
RD
Registered dietitian
2451 W Grapevine Mills Cir # 1079
Call 469-444-0715NPI 1881570737
Megan Guynn, RDN
RD
Registered dietitian
3900 Grapevine Mills Pkwy Unit 3233
Call 425-358-1479NPI 1568133593
Rebecca Hansen-Quiggle, R.D
RD
Registered dietitian
1518 Overlook Dr
Call 817-524-8820NPI 1285981209
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Zepbound cash price (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Commercial insurance (weight)
Often denied
On-label for obesity but frequently requires prior authorization
Medicare Part D
Not covered
Weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance with coverage only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Zepbound providers in Texas

NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Zepbound in other states

Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Zepbound in Texas

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]